Literature DB >> 16337236

Human osteoblasts produce cathepsin K.

Jami Mandelin1, Mika Hukkanen, Tian-Fang Li, Matti Korhonen, Mikko Liljeström, Tarvo Sillat, Roeland Hanemaaijer, Jari Salo, Seppo Santavirta, Yrjö T Konttinen.   

Abstract

Healthy bone is a rigid yet living tissue that undergoes continuous remodeling. Osteoclasts resorb bone in the remodeling cycle. They secrete H(+)-ions and proteinases to dissolve bone mineral and degrade organic bone matrix, respectively. One of the main collagenolytic proteinase in osteoclasts is cathepsin K, a member of papain family cysteine proteinases. Recently, it has been shown that osteoblasts may contribute to organic matrix remodeling. We therefore investigated their ability to produce cathepsin K for this action. Trabecular bone samples were collected from patients operated due to a fracture of the femoral neck. Part of the bone was decalcified and the rest was used for cell isolation. Sections from the decalcified bone were immunostained with antibodies against cathepsin K. Isolated cells were characterized for their ability to form mineralized matrix and subsequently analyzed for their cathepsin K production by Western blotting and quantitative RT-PCR. Osteoblasts, bone lining cells and some osteocytes in situ showed cathepsin K immunoreactivity and osteoblast-like cells in vitro produced cathepsin K mRNA and released both 42 kDa pro- and 27 kDa processed cathepsin K to culture media. Osteoblastic cathepsin K may thus contribute to collagenous matrix maintenance and recycling of improperly processed collagen I. Whether osteoblastic cathepsin K synthesis has consequences in diseases characterized by abnormal bone matrix turnover remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16337236     DOI: 10.1016/j.bone.2005.10.017

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  27 in total

1.  Processing of CXCL12 by different osteoblast-secreted cathepsins.

Authors:  Nicole D Staudt; Andreas Maurer; Bärbel Spring; Hubert Kalbacher; Wilhelm K Aicher; Gerd Klein
Journal:  Stem Cells Dev       Date:  2012-01-04       Impact factor: 3.272

2.  Release of prostaglandin E(1) from N-(2-hydroxypropyl)methacrylamide copolymer conjugates by bone cells.

Authors:  Huaizhong Pan; Jihua Liu; Yuanyi Dong; Monika Sima; Pavla Kopecková; Maria Luisa Brandi; Jindrich Kopecek
Journal:  Macromol Biosci       Date:  2008-07-07       Impact factor: 4.979

3.  Osteocytes Acidify Their Microenvironment in Response to PTHrP In Vitro and in Lactating Mice In Vivo.

Authors:  Katharina Jähn; Shilpa Kelkar; Hong Zhao; Yixia Xie; LeAnn M Tiede-Lewis; Vladimir Dusevich; Sarah L Dallas; Lynda F Bonewald
Journal:  J Bone Miner Res       Date:  2017-06-12       Impact factor: 6.741

4.  Interventional value of total flavonoids from Rhizoma Drynariae on Cathepsin K, a potential target of osteoporosis.

Authors:  Xiao-Lin Shi; Kang Liu; Lian-Guo Wu
Journal:  Chin J Integr Med       Date:  2011-07-03       Impact factor: 1.978

Review 5.  Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.

Authors:  Aline G Costa; Natalie E Cusano; Barbara C Silva; Serge Cremers; John P Bilezikian
Journal:  Nat Rev Rheumatol       Date:  2011-06-14       Impact factor: 20.543

6.  Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.

Authors:  Le T Duong
Journal:  Bonekey Rep       Date:  2012-05-02

7.  Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.

Authors:  Cristiano A F Zerbini; Michael R McClung
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

Review 8.  Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.

Authors:  Matthew T Drake; Bart L Clarke; Merry Jo Oursler; Sundeep Khosla
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

9.  Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation.

Authors:  Sutada Lotinun; Riku Kiviranta; Takuma Matsubara; Jorge A Alzate; Lynn Neff; Anja Lüth; Ilpo Koskivirta; Burkhard Kleuser; Jean Vacher; Eero Vuorio; William C Horne; Roland Baron
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

10.  Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats.

Authors:  S C Miller; H Pan; D Wang; B M Bowman; P Kopecková; J Kopecek
Journal:  Pharm Res       Date:  2008-08-29       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.